Vimarsana
Biggest News Aggregation in the World

Page 5 - Thomask Equels News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Thomask Equels. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Thomask Equels Today - Breaking & Trending Today

AIM ImmunoTech And 3 Other Stocks Under $1 Insiders Are Buying - AIM ImmunoTech (AMEX:AIM), Beasley Broadcast Group (NASDAQ:BBGI) - Vimarsana News

AIM ImmunoTech And 3 Other Stocks Under $1 Insiders Are Buying - AIM ImmunoTech (AMEX:AIM), Beasley Broadcast Group (NASDAQ:BBGI)

The Dow Jones closed lower by over 50 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

AIM ImmunoTech Inc. (NYSE:AIM) CEO Buys $14,898.84 in Stock - Vimarsana News

AIM ImmunoTech Inc. (NYSE:AIM) CEO Buys $14,898.84 in Stock

AIM ImmunoTech Inc. (NYSE:AIM – Get Free Report) CEO Thomas K. Equels purchased 33,861 shares of the business’s stock in a transaction that occurred on Monday, November 27th. The stock was bought at an average cost of $0.44 per share, with a total value of $14,898.84. Following the acquisition, the chief executive officer now owns […]

Insider Buying: AIM ImmunoTech Inc. (NYSE:AIM) CEO Buys 33,861 Shares of Stock - Vimarsana News

Insider Buying: AIM ImmunoTech Inc. (NYSE:AIM) CEO Buys 33,861 Shares of Stock

AIM ImmunoTech Inc. (NYSE:AIM – Get Free Report) CEO Thomas K. Equels purchased 33,861 shares of the company’s stock in a transaction dated Monday, November 27th. The stock was purchased at an average price of $0.44 per share, with a total value of $14,898.84. Following the transaction, the chief executive officer now owns 640,697 shares […]

Source: wkrb13.com
AIM ImmunoTech Completes Treatment of Last Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions - Vimarsana News

AIM ImmunoTech Completes Treatment of Last Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions

No severe adverse events reported to date Topline data expected as early as Q1 2024 OCALA, Fla., Nov. 21, 2023 -- AIM ImmunoTech Inc.   today announced the last subject has completed treatment...

AIM ImmunoTech to Discuss Third Quarter 2023 Financial Results on November 15, 2023 and Host Conference Call and Webcast - Vimarsana News

AIM ImmunoTech to Discuss Third Quarter 2023 Financial Results on November 15, 2023 and Host Conference Call and Webcast

09.11.2023 - OCALA, Fla., Nov. 09, 2023 (GLOBE NEWSWIRE) - AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), announced today that management will host a conference call and webcast to discuss the Company’s Q3 2023 operational and financial ...